BRIEF-DBV Technologies peanut allergy treatment fails to meet main goal in late-stage study

* DBV Technologies announces topline results of phase III clinical trial in peanut-allergic patients four to 11 years of age‍​
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.